m6A-centered Crosstalk Information
Mechanism of Crosstalk between m6A Modification and Epigenetic Regulation
| Crosstalk ID |
M6ACROT03058
|
[1] | |||
Histone modification
H3K18la
p300
METTL3
Direct
Enhancement
m6A modification
ACSL4
ACSL4
METTL3
Methylation
 : m6A sites
|
|||||
| m6A Modification: | |||||
|---|---|---|---|---|---|
| m6A Regulator | Methyltransferase-like 3 (METTL3) | WRITER | |||
| m6A Target | Long-chain-fatty-acid--CoA ligase 4 (ACSL4) | ||||
| Epigenetic Regulation that have Cross-talk with This m6A Modification: | |||||
| Epigenetic Regulation Type | Histone modification (HistMod) | ||||
| Epigenetic Regulator | Histone acetyltransferase p300 (P300) | WRITER | View Details | ||
| Regulated Target | Histone H3 lysine 18 lactylation (H3K18la) | View Details | |||
| Downstream Gene | METTL3 | View Details | |||
| Crosstalk Relationship | Histone modification → m6A | Enhancement | |||
| Crosstalk Mechanism | histone modification directly impacts m6A modification through modulating the level of m6A regulator | ||||
| Crosstalk Summary | Lactate regulates N6-methyladenosine (m6A) modification levels by facilitating p300/CBP-mediated Histone H3 lysine 18 lactylation (H3K18la) binding to the METTL3 promoter site. The METTL3-mediated m6A modification is enriched in Long-chain-fatty-acid--CoA ligase 4 (ACSL4), and its mRNA stability is regulated through a YTHDC1-dependent pathway. | ||||
| Responsed Disease | Sepsis-associated lung injury | ICD-11: NB30.4 | |||
In-vitro Model |
MLE-12
|
N.A. | Mus musculus | CVCL_3751 | |
Full List of Potential Compound(s) Related to This m6A-centered Crosstalk
| Histone acetyltransferase p300 (P300) | 2 Compound(s) Regulating the Target | Click to Show/Hide the Full List | ||
 Compound Name |
CCS1477 | Phase 1/2 | [2] | |
|---|---|---|---|---|
| Synonyms |
CCS-1477; CBP-IN-1; 2222941-37-7; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-((1r,4S)-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one; SCHEMBL20094038; SCHEMBL21515367; SCHEMBL22134021; EX-A3687; NSC818619; NSC-818619; HY-111784; CS-0091862; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-(trans-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one
Click to Show/Hide
|
|||
| MOA | Inhibitor | |||
| External Link | ||||
| Compound Name |
FT-7051 | Phase 1 | [3] | |
| MOA | Inhibitor | |||
| External Link | ||||
References